Issue Date: 01/2018

Version No: 2 Page 1 of 16



SECTION 1: IDENTIFICATION				
1.1 Product identifier				
Product name:	Atipam® (5.0 mg/ml Solution for Injection)			
Synonyms:	Revazol [NO, ES, PT]			
Proper Shipping name:	Not Available			
Other means of identification:	None			
1.2 Relevant identified uses	of the substances or mixture and uses advised against			
Recommended uses:	A selective α2-antagonist and is indicated for reversal of the sedative effects of medetomidine and dexmedetomidine in cats and dogs.			
Uses advised against:	The product should not be used in: • Breeding animals • Animals suffering from liver- or renal diseases The safety of the product has not been documented adequately during pregnancy and lactation. Therefore the use is not recommended during pregnancy and lactation.			
1.3 Details of the supplier of the substance or mixture				
Registered company name:	Eurovet Animal Health BV			
Address:	Handelsweg 25 5531 AE Bladel The Netherlands			
Telephone:	+31 (0) 497 544 300			
Fax:	+31 (0) 497 544 302			
Email:	Not available			
Website	www.dechra.com			
Distributor name (Canada):	Dechra Veterinary Products			
	1 Holiday Ave, East Tower, Suite 345 Pointe-Claire, QC H9R 5N3 Canada			
Telephone:	+1 (855) 332 9334			
Website:	www.dechra.ca			
Email:	Not Available			
1.4 Emergency Telephone N	umbers			
Dechra (US):	+1 (866) 933 2472			
Dechra (CA):	+1 (855) 332 9334			

Product Name: Atipam[®] (5.0 mg/g Solution for Injection)

Issue Date: 01/2018 Version No: 2 Page 2 of 16



SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Not considered a hazardous mixture according to Reg. (EC) No 1272/2008 and their amendments. Not classified as Dangerous Goods for transport purposes.

DSD Classification (EU):	Not Available
DPD Classification (EU)1:	Not Available
Classification according to regulation (EC) No 1272/2008 [CLP] (EU) ¹ :	

2.2 Label Elements

Signal Word: NOT APPLICABLE

Hazard Statement(s)

Not Applicable

Additional Statement(s)

Not Applicable

Precautionary Statement(s) Prevention:

Not Applicable

Precautionary Statement(s) Response:

Not Applicable

Precautionary Statement(s) Storage:

Not Applicable

Precautionary Statement(s) Disposal:

Not Applicable

2.3 Other Hazard Information

REACH - Art.57-59: The mixture does not contain Substances of Very High Concern (SVHC) at the SDS print date.

SECTION 3: INFORMATION ON THE INGREDIENTS

3.1 Substances

See section below for composition of mixtures

3.2 Mixtures

1.CAS No 2.EC Number 3.Index Number 4. EACH Number	% Weight	Name	Classification according to regulations (EC) No 1272/2008 [CLP] (EU)
 1. 104075-48-1 2. Not Available 3. Not Available 4. Not Available 	0.5	Atipamezole hydrochloride (equivalent to 4.27mg atipamezole hase)	Acute toxicity (oral) category 3; H301 ¹

Product Name: Atipam® (5.0 mg/g Solution for Injection)

Issue Date: 01/2018

Version No: 2 Page 3 of 16



1. 99-76-3 2. 202-785-7 3. Not available 4. 01-2119463264-40- XXXX/01- 2120065912-54-XXXX	0.1	Methyl parahydroxybenzoat e	Skin Corrosion/Irritation Category 2, Eye Irritation Category 2, Specific target organ toxicity - single exposure Category 3 (respiratory tract irritation), Chronic Aquatic Hazard Category 2; H315, H319, H335, H411 [1]
N/a	Proprietary	Other ingredients	N/a
Legend:	1. Classified by Chemwatch		

SECTION 4: FIRST AID MEASURES		
4.1 Description of first a	id measures	
Eye contact:	Due to the potent pharmacological activity of atipamezole, skin, eye and mucous membrane contact with this product should be avoided. In case of accidental contact of the product with the eyes rinse abundantly with fresh water. Seek medical attention if irritation persists.	
Skin contact:	Due to the potent pharmacological activity of atipamezole, skin, eye and mucous membrane contact with this product should be avoided. In case of accidental contact of the product with the skin rinse abundantly with fresh water. Seek medical attention if irritation persists. Remove contaminated clothes that are in direct contact with the skin.	
Inhalation:	Due to physical form of this product, inhalation exposure is unlikely. However, if this product causes irritation to the mucous membranes, seek medical attention.	
Ingestion:	Due to the potent pharmacological activity of atipamezole, skin, eye and mucous membrane contact with this product should be avoided. In case of accidental ingestion, seek medical attention if irritation persists.	
Self-injection:	Care should be taken to avoid accidental ingestion or self- injection. In case of accidental ingestion or self-injection, seek medical advice immediately and show the package leaflet to the physician.	
4.2 Most important symp	otoms and effects, both acute and delayed	
See Section 11		
	ate medical attention and special treatment needed	

4.3 Indication of immediate medical attention and special treatment needed Treat symptomatically.

Product Name: Atipam® (5.0 mg/g Solution for Injection)

Issue Date: 01/2018

Version No: 2 Page 4 of 16



SECTION 5: FIRE FIGHTING MEASURES		
5.1 Extinguishing media		
Suitable:	Water spray, carbon dioxide, dry chemical and foam, as appropriate for surrounding fire and materials.	
Unsuitable:	None.	
5.2 Special hazards arisin	g from the substance or mixture	
Fire incompatibility:	None known	
5.3 Special protective actions for fire-fighters:		
Firefighting:	Alert Fire Brigade and tell them location and nature of hazard. Wear full breathing apparatus and self-contained breathing apparatus. Prevent, by any means available, spillage from entering drains or water courses.	
Fire / explosion hazard:	Non-combustible.	
	Not considered a significant fire risk, however containers may burn.	

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

For information on protective equipment, see section 8.

6.2 Environmental Precautions

Do not allow product to reach sewage system or any water course. Inform respective authorities in case of seepage into water course or sewage system. Do not allow to enter sewers/ surface or ground water.

6.3 Methods and material for containment and cleaning up

Minor Spills:	Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment. Contain and absorb spill with sand, earth, inert material or vermiculite.
Major Spills:	Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of the hazard. Contain and absorb spill with sand, earth, inert material or vermiculite. Prevent, by any means available, spillage from entering drains or water course. Large spills should be collected into an appropriate container for waste disposal.

Version No: 2 Page 5 of 16



SECTION 7: HANDLING AND STORAGE			
7.1 Precautions for safe h	7.1 Precautions for safe handling		
Safe Handling:	Wear suitable protection gloves and clothing when handling the product. When handling, DO NOT eat, drink or smoke. Always wash hands with water after handling. Observe manufacturer's storage and handling recommendations.		
Other Information:	Keep out of the reach and sight of children.		
7.2 Conditions for safe sto	7.2 Conditions for safe storage, including any incompatibilities		
Suitable Container:	Shelf-life of the veterinary medicinal product as packaged for sale: 3 years. Shelf-life after first opening the immediate packaging: 28 days.		
Storage incompatibility:	Unknown.		
7.3 Specific end uses			
Not available			

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION				
8.1 Control parameter	8.1 Control parameters			
DERIVED NO EFFECT	LEVEL - DI	NEL (EU)		
Not Available				
PREDICTED NO EFFE	CT LEVEL -	PNEC (EU)		
Not Available	Not Available			
OCCUPATIONAL EXPOSURE LIMITS (OEL)				
INGREDIENT DATA:				
Not Available				
EMERGENCY LIMITS:				
Ingredient	Material Name	TEEL-1	TEEL-2	TEEL-3
Not Available				

Version No: 2 Page 6 of 16



8.2 Exposure controls	
	The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the particular risk.
Personal protection:	
Eye and face protection:	Safety glasses with side shields / chemical goggles
Skin protection:	See hand protection below
Hands/ feet protection:	No special equipment needed when handling small quantities. OTHERWISE: Wear chemical protective gloves
Body protection:	Wear appropriate clothing
Other protection:	No special equipment needed when handling small quantities
Thermal hazards:	Not available
Respiratory protection:	Not applicable
8.3 Environmental exposure of See Section 12	controls

Product Name: Atipam® (5.0 mg/g Solution for Injection)

Issue Date: 01/2018

Version No: 2 Page 7 of 16



SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance: Atipam®: Clear, colourless solution

Container: Cardboard box with 1 clear glass type I vial of 5, 10 or 20ml, with a teflon coated

halogenated rubber stopper and aluminium cap.

Physical state: Atipam®: liquid

Odour: Not available

Odour Threshold: Not available pH (as supplied): Not available

Melting point / freezing point (degrees C): Atipamezole hydrochloride Melting Point 220

degrees C

Initial boiling point and boiling range: Not available

Flash Point: In water – no flash point. Evaporation rate: Not available Flammability: Not available

Upper/lower flammability or explosive limits: Not available

Vapour pressure: Not available

Relative Density (at degrees C): Not available

Solubility in water and solvents (mg/l): Not available

Vapour density: Not available

Auto ignition temperature (degrees C): Not available Decomposition temperature (degrees C): Not available

Viscosity: (degrees C): Not available Explosive properties: Not available Oxidising properties: Not available Partition Coefficient: Not available

Molecular weight: Atipamezole hydrochloride: 248.75

Taste: Not available

Surface tension: Not available **Volative component:** Not available

Gas group: Not available pH as a solution: Not available

VOC g/L: Not available

9.2 Other information

Not Available

10: REACTIVITY AND STABILITY		
10.1 Reactivity:	See Section 7	
10.2 Chemical stability:	Product is considered stable. Hazardous polymerisation will not occur.	
10.3 Possibility of hazardous reactions:	See section 7.	
10.4 Conditions to avoid:	See Section 7.	

Version No: 2 Page 8 of 16



10.5 Incompatible materials:	See section 7.
10.6 Hazardous decomposition:	See Section 5.

ECTION 11: TOXICOL	OGICAL INFORMATION		
Inhalation:	Due to the potent pharmacological activity of atipamezole, skin, eye- and mucous membrane- contact with this product should be avoided.		
Ingestion:	Care should be taken to avoid accidental ingestion or self-injection. Due to the potent pharmacological activity of atipamezole, skin, eyeand mucous membrane- contact with this product should be avoided.		
Skin contact:	unlikelyCare should be taken to avoid accidental ingestion or self-injection. Due to the potent pharmacological activity of atipamezole, skin, eye- and mucous membrane- contact with this product should be avoided.		
Eye contact:	Due to the potent pharmacological activity of atipamezole, skin, eye- and mucous membrane- contact with this product should be avoided.		
Chronic:	Long-term exposure to the product is not thought to produce chronic effects adverse to the health (as classified by EC Directives using animal models); nevertheless exposure by all routes should be minimized as a matter of course		
Atipam®:	Acute toxicity	Irritation	
	Not Available	Not Available	
Atipamezole hydrochloride:	Acute toxicity	Irritation	
	Oral (rat) LD ₅₀ : 80 mg/kg* ¹	Eye: moderate Skin: moderate	
Methyl paraben	Toxicity	Irritation	
	Oral (rat) LD50: 2100 mg/kg*1	Not Available	
	l		

Product Name: Atipam® (5.0 mg/g Solution for Injection)

Issue Date: 01/2018 Version No: 2

Aspiration hazard:

Not available

Page 9 of 16



SECTION 11: TOXICOLOGICAL INFORMATION 1.* Value obtained from manufacturer's SDS. Unless otherwise specified, data extracted from RTECS - Register of Toxic Effect of chemical Substances **Acute toxicity:** Not Available Skin corrosion/ irritation: Not Available Serious eye damage/ irritation: Not available Respiratory or skin sensitization: Not available Germ cell mutagenicity: Not available Carcinogenicity: Not available Reproductive toxicity: Not available STOT - single exposure: Not available **STOT**–repeated exposure: Not available

SECTION 12: ECOLOGICAL INFORMATION					
12.1 Toxicity					
Ingredient	Endpoint	Test duration (hr)	Species	Value	Source
Atipamezole hydrochloride	Not Available	Not Available	Not Available	Not Available	Not Available

Issue Date: 01/2018

Version No: 2 Page 10 of 16



Methyl paraben	EC50	48	Crustacea	41.1mg/L	1
Methyl paraben	NOEC	504	Crustacea	0.2mg/L	2
Legend:	Legend: Extracted from 1. US EPA, Ecotox database – Aquestic toxicity Data 2. Europe ECHA Registered Substances -				
12.2 Persisten	ce and degra	dability			
Ingredient		Persistence:	Water/Soil	Persistence	e: Air
Methyl paraber	1	LOW		LOW	
12.3 Bioaccum	nulative poter	ntial			
Ingredient	Ingredient Bioaccumulation				
Methyl paraben			LOW (LogKOW = 1.96)		
12.4 Mobility in	n Soil				
Ingredient			Mobility		
Methyl paraben		LOW (LogKOW = 125.6)			
12.5 Results of PBT and vPvB assessment					
Not Available					
12.6 Other adverse effects					
Not Available					

SECTION 13: DISP	SECTION 13: DISPOSAL CONSIDERATIONS		
13.1 Waste treatmo	ent methods		
packaging	Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with national requirements.		
	Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area.		
	Ensure that the disposal of material is carried out in accordance with Hazardous Products Regulations (Canada, 2015).		
Waste Treatment Options:			
Sewage Disposal			

Safety Data Sheet Product Name: Atipam® (5.0 mg/g Solution for Injection) Version No: 2

Page 11 of 16



SECTION 14: TRAN	ISPORT INFORMATION		
Labels required:	None		
Marine pollutant:	NO		
Hazchem:	Not Applicable		
Land transport (AD	PR):		
14.1 UN Numbe	r N/a		
14.2 UN Prope Shipping Nam			
14.3 Transpor		N/a	
hazard class(es	Sub risk	N/a	
14.4 Packing grou	p N/a		
14.5 Environmenta hazard			
		-	
14 6 Special	Special provisions	ıN/a	

14.6 Special precautions for	Special provisions	N/a
user	Classification code	N/a
	Hazard Label	N/a
	Special provisions	N/a
	Limited quantity	N/a
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a	
Air transport (ICAO-	ATA / DGR):	
14.1 UN Number	N/a	
14.2 UN Proper Shipping Name	N/a	
14.3 Transport	ICAO/IATA Class	N/a
hazard class(es)	ICAO / IATA Sub risk	N/a
	ERG Code	N/a
14.4 Packing group	N/a	
14.5 Environmental hazards	N/a	

Version No: 2 Page 12 of 16



14.6 Special	Special provisions	N/a	
precautions for user	Cargo only packing instructions	N/a	
	Cargo only maximun qty/pack	n N/a	
	Passenger and cargonackaging instruction		
	Passenger and cargo maximum qty/pack	o N/a	
	Passenger and cargo limited quantity packing instructions	o N/a	
	Passenger and cargo limited maximum qty/pack	o N/a	
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a		
Sea transport (IMDG	-Code / GGVSee):		
14.1 UN Number	N/a		
14.2 UN Proper Shipping Name	N/a		
14.3 Transport	IMDG Class	N/a	
hazard class(es)	IMDG Sub risk	N/a	
14.4 Packing group	N/a		
14.5 Environmental hazards	N/a		
	EMS Number	N/a	
precautions for user	Special provisions	N/a	
	Limited quantities	N/a	
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a		

Product Name: Atipam® (5.0 mg/g Solution for Injection)

Issue Date: 01/2018

Version No: 2 Page 13 of 16



Inland waterways tra	nsport (ADN):	
14.1 UN Number	N/a	
14.2 UN Proper Shipping Name	N/a	
14.3 Transport hazard class(es)	N/a N/a	
14.4 Packing group	N/a	
14.5 Environmental hazard	N/a	
	Classification Code	N/a
precautions for user	Special provisions	N/a
	Limited quantity	N/a
	Equipment required	N/a
	Fire cones number	N/a
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a	

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations / legislation specific for the substance or mixture

ATIPAMEZOLE HYDROCHLORIDE (104075-48-1) IS FOUND ON THE FOLLOWING REGULATORY LISTS:

N/a

METHYL PARABEN (99-76-3) IS FOUND ON THE FOLLOWING REGULATORY LISTS:

EU European Chemicals Agency (ECHA) Community Rolling Action Plan (CoRAP) List of Substances

European Customs Inventory of Chemical Substances ECICS (English)

This safety data sheet is in compliance with the following EU legislation and its adaptations - as far as applicable-: 98/24/EC, 92/85/EC, 94/33/EC, 91/689/EEC, 1999/13/EC

15.2 Chemical Safety Assessment

ECHA SUMMARY

Ingredient	CAS number	Index Number	ECHA Dossier
Atipamezole Hydrochloride	104075-48-1	Not Available	Not Available

Product Name: Atipam® (5.0 mg/g Solution for Injection)

Issue Date: 01/2018

Version No: 2 Page 14 of 16



Harmonization (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Acute Tox. 3	GHS06, Dgr	H301, H311, H331
Ingredient	CAS number	Index Number	ECHA Dossier
Methyl paraben	99-76-3	Not Available	Not Available
Harmonization (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Skin Irrit. 2; Eye Irrit. 2; STOT SE 3	GHS07; Wng	H315; H319; H335

Harmonization Code 1 = The most prevalent classification. Harmonization Code 2 = The most severe classification

Australia - AICS	N (atipamezole hydrochloride)
Canada - DSL	N (atipamezole hydrochloride)
Canada - NDSL	N (methyl paraben; water; sodium chloride, atipamezole hydrochloride)
China - IECSC	N (atipamezole hydrochloride)
Europe - EINEC / ELINCS / NLP	N (atipamezole hydrochloride)
Japan - ENCS	N (methyl paraben; atipamezole hydrochloride)
Korea - KECI	N (atipamezole hydrochloride)
New Zealand - NZIoC	Y
Philippines - PICCS	N (atipamezole hydrochloride)
USA - TSCA	N (atipamezole hydrochloride)
Legend:	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

Product Name: Atipam® (5.0 mg/g Solution for Injection)

Issue Date: 01/2018

Version No: 2 Page 15 of 16



SECTION 16: OTHER INFORMATION

The SDS is written in accordance to guidelines specified by REACH, GHS and ECHA.

Full text Risk and Hazard codes:

H301	Toxic if swallowed.
H302	Harmful if swallowed.
H311	Toxic in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H331	Toxic if inhaled.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H335	May cause respiratory irritation.
H341	Suspected of causing genetic defects.
H360D	May damage the unborn child.
H412	Harmful to aquatic life with long lasting effects.

Product Name: Atipam® (5.0 mg/g Solution for Injection)

Issue Date: 01/2018

Version No: 2 Page 16 of 16



For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

EN 166 Personal eye-protection

EN 340 Protective clothing

EN 374 Protective gloves against chemicals and micro-organisms

EN 13832 Footwear protecting against chemicals

EN 133 Respiratory protective devices

Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average PC—STEL: Permissible Concentration-Short Term Exposure Limit

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit

IDLH: Immediately Dangerous to Life or Health Concentrations

The information provided in this Safety Data Sheet has been compiled by Dechra Ltd using a number of different sources, and is correct to the best of its knowledge, information and belief as at the date of its publication. However, Dechra Ltd makes no warranties, express or implied, in relation to the information set out in this Safety Data Sheet, including, without limitation, as to its accuracy or completeness.

The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.

Copyright, 2017, Dechra Ltd. All rights reserved.

Copying and/or downloading of this information for the purpose of properly utilizing Dechra Ltd products is permitted provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained from Dechra Ltd, and (2) neither the copy nor the original is resold or otherwise distributed for the purposes of making a profit thereon.